JANX News and Press, Janux Therapeutics Inc. From 05/09/23

2023-05-09 04:02:31 ET Summary Despite the recent rebound, US-listed biotech stocks valuations are still "down to earth" compared to the strong recovery from the Covid-19 crisis. Relatively low market valuations offer an opportunity to add to positions in biotechnology stocks with...

2023-04-28 15:00:41 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today an...

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today an...

2023-04-06 10:11:48 ET Shares of clinical-stage biotech Janux Therapeutics ( NASDAQ: JANX ) inched higher Thursday after Wedbush launched its coverage with an Outperform recommendation, citing the potential of its platform technology. Janux ( JANX ) develops immunotherapies ...

2023-03-15 11:44:07 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stoc...

2023-03-10 16:37:09 ET Janux Therapeutics press release ( NASDAQ: JANX ): Q4 GAAP EPS of -$0.39 beats by $0.10 . Revenue of $2.85M (+75.9% Y/Y) beats by $2.04M . For further details see: Janux Therapeutics GAAP EPS of -$0.39 beats by $0.10, revenue of $2....

-Interim clinical update from Phase 1 trial of JANX007 expected in 2H 2023- -FDA clearance granted for Investigational New Drug (IND) application for EGFR-TRACTr (JANX008)- -$327.0 million in year-end cash and cash equivalents and short-term investments- Janux Therapeutics...

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today an...

Janux Therapeutics ( NASDAQ: JANX ) said it submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) seeking to start a trial of cancer drug JANX008 in humans. The company added that  JANX008 is in development to treat EGFR-e...